Sign in

Berkeley Limketkai, MD PhD

@berkeleydoc.bsky.social
171 followers 69 following 7 posts

Gastroenterologist with clinical and research focuses in IBD, nutrition, data, AI. Serving the world, one gut at a time @UCLAHealth. Views are my own.

PostsRepliesMedia
Reposted by Berkeley Limketkai, MD PhD
UCLA Department of Medicine @domucla.bsky.social · 27/02/2026
Meet Gail Thames, division administrator at the UCLA Center for Human Nutrition! From divisional administration and budgeting to clinical trial management and organizational strategy, Gail plays a vital role in advancing our mission. Learn more: uclahs.fyi/3Os0nFD
211
Reposted by Berkeley Limketkai, MD PhD
UCLA Department of Medicine @domucla.bsky.social · 21/05/2025
Solomon Scholars Research Day 2025 was a success! Residents across our seven UCLA-affiliated internal medicine programs gathered to share innovative research and case studies. Watch the recap video to learn from some of the presenters about their projects: uclahs.fyi/4moVfyu
011
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 08/05/2025
🔥off the press: @amcollegegastro.bsky.social guideline on nutrition/malnutrition for liver disease. pubmed.gov/40314389
pubmed.gov
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease - PubMed
Malnutrition, defined as deficiency, excess, or imbalance of nutrients, is a common complication in patients with liver disease, especially those with cirrhosis. Malnutrition may present as an isolate...
011
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 08/05/2025
Mark Baniqued shares our findings of food insecurity among individuals with #IBD in US (13% with #IBD vs. 8% without IBD). Diet therapies don't work for patients who cannot even afford them. #DDW2025 @ddwmeeting.bsky.social
000
Reposted by Berkeley Limketkai, MD PhD
American Gastroenterological Association (AGA) @amergastroassn.bsky.social · 24/04/2025
🚨 Our new commentary in aga-gastro.bsky.social highlights best practices for diagnosing, treating, and monitoring Crohn’s perianal fistula. 📖 Read more: gastro.org/news/best-pr.... #GIsky
021
Reposted by Berkeley Limketkai, MD PhD
aga-gihn.bsky.social @aga-gihn.bsky.social · 14/04/2025
Dr. Dana Lukin provides takeaways from this study published in @aga-gastro.bsky.social that found wearable devices like the Apple Watch and Fitbit may help predict #IBD flares. www.mdedge.com/gihepnews/ar...
021
Reposted by Berkeley Limketkai, MD PhD
The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 14/04/2025
New research - Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial www.thelancet.com/journals/lan... #GastroSky #MedSky #IBDSky
thelancet.com
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
Appendicectomy is superior to standard medical therapy alone in maintaining remission in patients with ulcerative colitis.
071
Reposted by Berkeley Limketkai, MD PhD
American Gastroenterological Association (AGA) @amergastroassn.bsky.social · 13/02/2025
🚨 NIH funding changes threaten #GIResearch labs and the future of GI patient care! 🚨 AGA President Maria T. Abreu calls for action. Share your story about how these changes impact your work. Let's protect the future of digestive disease treatment! buff.ly/40WPmyC
086
Reposted by Berkeley Limketkai, MD PhD
IBD Doctor @ibddoctor.bsky.social · 31/01/2025
For #IBD folks dealing with pain, this could be a big deal. www.nature.com/articles/d41... Lots of data on surgical pain. Affects sodium channels, not opioid receptors. Availability and price/coverage TBD. @ccyanetwork.bsky.social @crohnsandcolitisau.bsky.social @crohnsdiseaseuk.bsky.social
nature.com
FDA approves new non-opioid pain drug
Discover the world’s best science and medicine | Nature.com
0113
Reposted by Berkeley Limketkai, MD PhD
Rob Brierley @robbrierley.bsky.social · 17/01/2025
FDA approves mirikizumab for moderately to severely active Crohn’s disease www.prnewswire.com/news-release... #GastroSky #MedSky #IDSky
prnewswire.com
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
073
Reposted by Berkeley Limketkai, MD PhD
The Lancet @thelancet.com · 17/01/2025
The spread of health misinformation and disinformation poses a serious threat to public health. How can we respond to the danger and combat the tide of misinformation and disinformation to protect public health? Find out more in our latest Editorial: tinyurl.com/mtf95p25
Cover of The Lancet's Jan 18th, 2025 issue. Quote reads: "Disinformation has become a deliberate instrument to attack and discredit scientists and health professionals for political gains. The effects are destructive and damaging to public health."
9332198
Reposted by Berkeley Limketkai, MD PhD
American Gastroenterological Association (AGA) @amergastroassn.bsky.social · 09/01/2025
🌟 Our new clinical practice update on endoscopic enteral access is out! Discover the best practices for tube selection, access points, and feeding methods for patients with inadequate oral intake. #GIsky #ClinicalPracticeUpdate
041
Reposted by Berkeley Limketkai, MD PhD
American Gastroenterological Association (AGA) @amergastroassn.bsky.social · 11/12/2024
Say hello to @aga-gihn.bsky.social, AGA's official newspaper, on bsky and follow for articles on the latest in GI!
053
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 09/12/2024
Too bad filgotinib was not superior for all wk 10 primary endpoints for #CD. This may have partly been due to mandatory steroid tapering not starting until wk 14 (unlike U-EXCEL/U-EXCEED upadacitinib trials that started at wk 4). Filgotinib will now have a higher bar to climb for positioning.
000
Reposted by Berkeley Limketkai, MD PhD
American Gastroenterological Association (AGA) @amergastroassn.bsky.social · 26/11/2024
🆕 AGA living guideline for moderate-to-severe #UlcerativeColitis. ⤵️ Sidd Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social, @ashwinmdibd.bsky.social, @frankiscottmd.bsky.social & Edward Loftus rank 1️⃣2️⃣ therapies by efficacy. gastro.org/clinical-gui...
gastro.org
Living guideline for moderate-to-severe ulcerative colitis
New clinical guideline on pharmacological management of moderate-to-severe ulcerative colitis.
192
Reposted by Berkeley Limketkai, MD PhD
Malcolm Tan @ibdgastrodocsg.bsky.social · 24/11/2024
Real-world data of JAK-inhs from Japan, comparing UPA, FIL and TOF - UPA seems to be most effective, even in pts with previous exposure to ≥2 advanced therapies - UPA: acne is quite common (23%), a relevant side-effect for some patients - FIL = TOF #IBDSky onlinelibrary.wiley.com/doi/10.1111/...
072
Reposted by Berkeley Limketkai, MD PhD
Jon Lim, FRCP PhD @drjonlim.bsky.social · 23/11/2024
🎨 In case anyone need… The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏! Check it out 👇 bioart.niaid.nih.gov
441198491
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 23/11/2024
Hopefully, we can also see Crohn’s & Colitis Foundation here in the not too distant future? @alanmoss.bsky.social
010
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 23/11/2024
AGA has joined the party. Welcome!
200
Reposted by Berkeley Limketkai, MD PhD
Alan Moss MD @alanmoss.bsky.social · 21/11/2024
Early bird rate for #CCCongress25 ends on Wednesday ⏰ 🐐 @umamahadevanibd.bsky.social keynote on IBD & 🤰 👩‍🏫 #IBD A-Z 💪 Surgery prehabilitation 🚨Ultrasound training course with #IUSCAN #IBUS @edelblumlab.bsky.social #AGA crohnscolitiscongress.org
184
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 20/11/2024
Hot🔥 off the press! Living guidelines for pharmacological treatment of #UC @jhaydek.bsky.social presents an excellent skytorial
030
Reposted by Berkeley Limketkai, MD PhD
Frank I. Scott, MD MSCE @frankiscottmd.bsky.social · 19/11/2024
The AGA’s first-ever living guideline formoderate-to-severe #UlcerativeColitis led by S Singh, @berkeleydoc.bsky.social, @manasiagrawal.bsky.social, @jhaydek.bsky.social , @ashwinmdibd, @EdwardLoftus2 and myself prioritizes early use of advanced txs over a step-up approach. ow.ly/t2Ru50UahEi
ow.ly
DEFINE_ME
1115
Reposted by Berkeley Limketkai, MD PhD
Frank I. Scott, MD MSCE @frankiscottmd.bsky.social · 12/11/2024
Towards better understanding how we should position advanced tx in UC: Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis - Gastroenterology www.gastrojournal.org/article/S001...
091
Berkeley Limketkai, MD PhD @berkeleydoc.bsky.social · 16/11/2024
And so begins my journey in this new community. Hopefully, Blue Sky lives up to its name. 😊
010